Insulin Treatment Cannot Promote Lipogenesis in Rat Fetal Lung in Gestational Diabetes Mellitus Because of Failure to Redress the Imbalance Among SREBP-1, SCAP, and INSIG-1

2018 ◽  
Vol 37 (3) ◽  
pp. 264-270 ◽  
Author(s):  
Jinyan Li ◽  
Guanhua Qian ◽  
Xiaocui Zhong ◽  
Tinghe Yu
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Insulin Treatment ◽  
Fetal Lung

scholarly journals Can Common Clinical Parameters Be Used to Identify Patients Who Will Need Insulin Treatment in Gestational Diabetes Mellitus?

Diabetes Care ◽  
2011 ◽  
Vol 34 (10) ◽  
pp. 2214-2216 ◽  
Author(s):  
T. Pertot ◽  
L. Molyneaux ◽  
K. Tan ◽  
G. P. Ross ◽  
D. K. Yue ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Insulin Treatment ◽  
Clinical Parameters

scholarly journals Risk Factors for the Requirement of Antenatal Insulin Treatment in Gestational Diabetes Mellitus

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Mayu Watanabe ◽  
Akihiro Katayama ◽  
Hidetoshi Kagawa ◽  
Daisuke Ogawa ◽  
Jun Wada
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Insulin Therapy ◽  
Pregnant Women ◽  
Plasma Glucose ◽  
Insulin Treatment ◽  
Diet Group ◽  
Glucose Levels

Poor maternal glycemic control increases maternal and fetal risk for adverse outcomes, and strict management of gestational diabetes mellitus (GDM) is recommended to prevent neonatal and maternal complications. However, risk factors for the requirement of antenatal insulin treatment (AIT) are not well-investigated in the pregnant women with GDM. We enrolled 37 pregnant women with GDM and investigated the risk for AIT by comparing the patients with AIT (AIT group;n=10) and without insulin therapy (Diet group;n=27). The 1-h and 2-h plasma glucose levels and the number of abnormal values in 75 g OGTT were significantly higher in AIT group compared with Diet group. By logistic regression analysis, plasma glucose level at 1-h was significant predictor for AIT and the odds ratios were 1.115 (1.004–1.239) using forward selection method and 1.192 (1.006–1.413) using backward elimination method. There were no significant differences in obstetrical outcomes and neonatal complications. 1-h plasma glucose levels in 75 g OGTT are useful parameters in predicting the requirement for AIT in GDM. Both maternal and neonatal complications are comparable in GDM patients with and without insulin therapy.

Evaluation of Fetal Lung Maturity by Quantitative Analysis (quantusFLM) in Women with Gestational Diabetes Mellitus

2018 ◽  
Vol 45 (5) ◽  
pp. 345-352
Author(s):  
Francisco López Sánchez ◽  
Elsa Delgado Sánchez ◽  
Inmaculada Duyos Mateo ◽  
María de la Cruz González Álvarez ◽  
Eugenia Antolín Alvarado ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Quantitative Analysis ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Fetal Lung ◽  
Fetal Lung Maturity ◽  
Lung Maturity

scholarly journals Efficacy and safety of metformin for the treatment of gestational diabetes: a new approach to the problem

2016 ◽  
Vol 19 (2) ◽  
pp. 164-170 ◽  
Author(s):  
Anna I. Sazonova ◽  
Roza M. Esayan ◽  
Oksana I. Kolegaeva ◽  
Zhanna R. Gardanova
Keyword(s):  
Diabetes Mellitus ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Insulin Treatment ◽  
Randomized Clinical Trials ◽  
Main Concern ◽  
Efficacy And Safety ◽  
New Approach ◽  
Diabetes Mellitus Treatment ◽  
Foetal Blood

Historically, the following two methods were used to treat gestational diabetes mellitus: non-medical life-style interventions (diet and increased physical activity) and insulin treatment when other interventions were not effective. The possibility of alternative types of treatment such as oral anti-diabetic drugs has been the source of debate in recent years. Metformin is an oral anti-diabetic drug that reduces insulin resistance, which is common during gestation and is considered one of the main pathways of glucose metabolism alteration during pregnancy. The main concern is that metformin can cross the placenta and is found unchanged in foetal blood. This is the reason why oral anti-diabetic drugs are contraindicated during pregnancy in many countries, including Russia (according to the 2012 Russian recommendations for gestational diabetes treatment). In recent years, many studies investigating the safety and efficacy of metformin for maternal and foetal health have been published. We will review recent randomized clinical trials and discuss new international clinical recommendations (FIGO, 2015) and new opportunities for gestational diabetes mellitus treatment. 

Sign in / Sign up

Export Citation Format

Share Document